In-Silico Design and Study of Novel Tetrahydro-β-Carbolines as Inhibitor of HIV-1 Reverse Transcriptase
Abstract
Abstract
In the present study, we have designed 50 novel tetrahydro-β-carboline derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Docking studies of designed analogs were performed by molecular modeling software AutoDock 4.2 using HIV-1 reverse transcriptase (PDB ID: 1RT2) as receptor. Lipinski rule of five parameters and toxicity parameters were derived through online servers Molinspiration and Osiris property explorer respectively. Docking parameters such as binding free energy and predicted inhibitory constant (Ki) values of designed analogs were compared with standard drug Efavirenz and TNK-651. Among the designed analogs, TBB-III-29, TBB-III-33, TBB-III-39, TBB-III-42, TBB-III-44, TBB-III-45, TBB-III-46, TBB-III-49 and TBB-III-50 showed significant binding free energy and predicted inhibitory constants with that of standard drug Efavirenz and TNK-651. These results also indicate that, the designed analogs adopt a similar orientation and share the same binding mode as that of some classical non-nucleoside reverse transcriptase inhibitors (NNRTIs) within the active site of non-nucleoside inhibitory binding pocket (NNIBP) of HIV-1 reverse transcriptase.
Keywords: AIDS, HIV-1 reverse transcriptase, docking, molecular properties, tetrahydro-β-carboline
Cite this Article
Ashok Penta, Subhash Chander, Sankaranarayanan Murugesan. In-Silico Design and Study of Novel Tetrahydro-β-Carbolines as Inhibitor of HIV-1 Reverse Transcriptase. Research & Reviews: A Journal of Drug Design & Discovery. 2016; 3(1): 19–30p.
Downloads
Published
Issue
Section
License
Copyright Transfer and Declaration Form (Please compile this form, sign and send by e-mail and post)
Journal Title:
Title of the Paper:
Corresponding Author’s Information: Name: Address:
E-mail:
Contact Number: I
t is herein agreed that: The copyright to the above-listed unpublished and original article is transferred to STM Journals. This copyright transfer covers the exclusive right to reproduce and distribute the contribution, including reprints, translations, photographic reproductions, microform, electronic form (offline, online), or any other reproductions of similar nature. I/We declare that above manuscript is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere. I/ We warrant(s) that his/her/their contribution is original, except for such excerpts from copyrighted works as may be included with the permission of the copyright holder and author thereof, that it contains no libelous statements, and does not infringe on any copyright, trademark, patent, statutory right, or propriety right of others. I/We will not publish his/her/their above said contribution anywhere else without the prior written permission of the publisher unless it has been changed substantially.I/We also agree to the authorship of the article in the following order:Author(s) Name Signature(s)1. ________________2. ________________3. ________________4. ________________The author(s) agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal (comments if any to the editor can be added below).
